Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience.

ABSTRACT:

Aims

The aim of this study is to evaluate the implementation of the cardiac amyloidosis (CA) clinical pathway on awareness among referring cardiologists, diagnostic delay, and severity of CA at diagnosis.

Methods and results

Patients with CA were retrospectively included in this study and divided into two periods: pre-implementation of the CA clinical pathway (2007-18; T1) and post-implementation (2019-20; T2). Patients' and disease characteristics were extracted from electronic health records and compared. In total, 113 patients (mean age 67.8 ± 8.5 years, 26% female) were diagnosed with CA [T1 (2007-18): 56; T2 (2019-20): 57]. The number of CA diagnoses per year has increased over time. Reasons for referral changed over time, with increased awareness of right ventricular h

SUBMITTER: Brons M 

PROVIDER: S-EPMC9242028 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature